In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lupin's US launches will drive growth in FY13; Q3 sales up 22%

This article was originally published in Scrip

Executive Summary

Nilesh Gupta, Lupin's group president, told Scrip that the company anticipates about 25 generic launches in the US in the next fiscal year, roughly half of these in the 'fairly lucrative' oral contraceptives segment. In the third quarter, Lupin launched three oral contraceptive products in the US, including the authorised generic for Femcon Fe from Warner Chilcott which has garnered a share of about 15-20%. Currently half of Lupin's 32 marketed generic products in the US rank number one by market share and 30 of the 32 are in the top three by market share, the company said. The company received seven ANDA approvals in the quarter including those for zidovudine, minocylcine ER, duloxetine DR and fenofibrate.

You may also be interested in...



India Lockdown: Early Signs of Manufacturing Strains But Resolutions Underway

Pharmaceutical manufacturing in India is facing some early stress amid the new 21-day lock-down but both the industry and government machinery are actively engaged and working together to ensure that disruptions are minimized in the ‘pharmacy of the world.’

India Bars Exports Of Hydroxychloroquine With Some Exceptions

India has prohibited exports of hydroxychloroquine, though with concessions in specific instances, days after a national task force recommended the drug for the prophylaxis of SARS-CoV-2 infections. Home market supplies of the drug also appear strained for now.

Alembic: Enough Inventory, China API Supplies Heading Back To Normalcy

Alembic says it is 'comfortably placed' in terms of inventories and is seeing improving API supplies from China. The only area of some concern is outbound logistics against a backdrop of flights being halted and population lock-downs.

Topics

Related Companies

UsernamePublicRestriction

Register

SC016057

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel